The de novo DNA methyltransferase 3A (DNMT3A) plays pivotal roles in hematopoietic differentiation. In this study, we followed the hypothesis that alternative splicing of DNMT3A has characteristic epigenetic and functional sequels. Specific DNMT3A 
Introduction
DNA methylation (DNAm) of CG dinucleotides (CpGs) is a key epigenetic process in cellular differentiation (Broske et al. 2009 ). Establishment of new DNAm patterns is particularly mediated by the methyltransferases DNMT3A and DNMT3B (Okano et al. 1999 ). Both de novo DNMTs are subject to extensive tissue-or developmental stagespecific alternative splicing (Weisenberger et al. 2002) and different variants can be coexpressed in the same cell (Van Emburgh and Robertson 2011) . There is evidence that alternative splicing of DNMTs affects enzymatic activity or binding specificity (Weisenberger et al. 2002; Choi et al. 2011; Duymich et al. 2016 ), but so far it is largely unclear if the different variants mediate different DNAm patterns and if they really possess specific functions in development.
DNMT3A is of particular relevance for hematopoietic differentiation. Conditional ablation of exon 19 of Dnmt3a in mice was shown to increase the hematopoietic stem cell pool and impairs their differentiation (Challen et al. 2011; . Furthermore, it has been shown that DNMT3A is the most frequently mutated gene in clonal hematopoiesis of the elderly and this was linked to a higher risk for hematological malignancies -indicating that aberrations in DNMT3A play a central role for clonal hematopoiesis (Genovese et al. 3 2014; Jaiswal et al. 2014; Xie et al. 2014) . However, the functional roles of specific DNMT3A variants in hematopoietic differentiation and malignancies have not been systematically compared.
Acute myeloid leukemia (AML) is frequently associated with genomic mutations in DNMT3A -either at the highly recurrent position R882 (Yamashita et al. 2010 ), or at other sites within this gene (Ley et al. 2010; Yoshizato et al. 2015) . These mutations are associated with poor prognosis and are used for risk stratification in AML (Ley et al. 2010; Ribeiro et al. 2012 ). In our previous study, we demonstrated that ~40% of AML patients have an aberrant hypermethylation within the DNMT3A gene (Jost et al. 2014 ).
This hypermethylation is also associated with poor prognosis in AML (Jost et al. 2014) and myelodysplastic syndromes (Mies et al. 2016 ) and was therefore termed "DNMT3A epimutation". Notably, mutations and the "epimutation" of DNMT3A resulted in downregulation of exons associated with transcript 2 (coding for DNMT3A2) (Jost et al. 2014 ). Furthermore, in vitro expansion of hematopoietic stem and progenitor cells (HSPCs) resulted in downregulation of DNMT3A transcript 2 (Weidner et al. 2013) . In this study, we followed the hypothesis that different isoforms of DNMT3A have distinct molecular and functional sequels and thereby affect hematopoietic differentiation and malignancy.
Results and Discussion

DNMT3A splice variants have transcript-specific DNA methylation signatures
So far, five protein coding transcripts of DNMT3A have been described: transcripts 1 and 3 (ENST00000264709.7 and ENST00000321117.9, respectively) have different transcription start sites, but code for the same full-length protein isoform, referred to as DNMT3A1; transcript 2 (ENST00000380746.8) is truncated at the N-terminus, and codes for the protein isoform DNMT3A2; transcript 4 (ENST00000406659.3), coding for DNMT3A4, is truncated at the C-terminus and lacks the catalytic active methyltransferase (MTase) domain, as well as the PWWP (Pro-Trp-Trp-Pro) and ADD (ATRX-DNMT3-DNMT3L) domain that can interact with various binding partners and chromatin modifications (Yang et al. 2015) . Recently, an additional transcript 5 was identified (ENST00000402667.1) that encodes for a similar isoform as DNMT3A2, but lacks the 2 nd exon of transcript 2. While we were able to amplify transcript 5, this 4 transcript does not have a unique exon for transcript-specific knockdown and therefore it was not considered for further analysis.
Initially, individual transcripts were knocked down (KD) in cord blood-derived CD34 + HSPCs with short hairpin RNAs (shRNAs) targeting exon 5 of transcripts 1 and 3 (shRNA Tr.1+3), exon 2 of transcript 2 (shRNA Tr.2), and exon 4 of transcript 4 (shRNA Tr.4; Fig. 1A ). As a control we used a shRNA containing a scrambled sequence.
Significant knockdown was validated by RT-qPCR with primers targeting transcriptspecific exons ( Fig. 1B ; n = 3). Additionally, DNMT3A transcripts 1+3, 2, and 4 were cloned into vectors for constitutive overexpression (OE) and delivered by lentiviral infection into additional three replicates of CD34 + HSPCs. Efficient overexpression was verified by RT-qPCR ( Fig. 1C ; n = 3).
To investigate if modulation of DNMT3A splice variants evokes transcript-specific epigenetic changes we analyzed global DNAm patterns. Knockdown of transcripts 1+3 resulted in 352 CpGs with significant DNAm changes compared to HSPCs infected with the scrambled control ( Fig. 1D ; Supplemental Table S1A ; n = 3; adj. P < 0.05); knockdown of transcript 2 evoked 8,905 significant DNAm changes ( Fig. 1E ;
Supplemental Table S1B ; n = 3, adj. P < 0.05); whereas knockdown of transcript 4, which does not comprise the MTase domain, did not result in any significant changes (Fig. 1F) . Downregulation of transcripts 1+3 resulted preferentially in hypomethylation, whereas downregulation of transcript 2 was rather associated with hypermethylation.
The latter is counterintuitive, but in line with preferential hypermethylation in reduced representation bisulfite sequencing (RRBS) data of Dnmt3a-null HSCs (Challen et al. 2011 ). Overall, the overlap of differential DNAm upon KD of transcripts 1+3 and KD of transcript 2 was relatively low and most of the changes seemed to be transcript-specific (Fig. 1G ). This is in line with previous reports indicating that DNMT3A1 is associated with heterochromatin, whereas DNMT3A2 is rather associated with euchromatin (Chen et al. 2002) , and that the two isoforms have different binding preferences in mouse embryonic stem cells (Manzo et al. 2017) . Downregulation of transcript 2 led to a significant hypermethylation of two CpGs within DNMT3A (cg20948740 and cg11354105; ∆β-value = 0.0505 and 0.0502, respectively; adj. P < 0.05) that are localized close to the epimutation of DNMT3A, which is frequently deregulated in AML (Jost et al. 2014) . Thus, the DNMT3A epimutation may not only result in downregulation of transcript 2 (Jost et al. 2014 ), but also the other way around. Furthermore, there is 5 recent evidence that DNMT3A itself interacts with splicing factors and impacts global alternative splicing patterns in HSCs (Ramabadran et al. 2017 ; and transcript 2:
hypermethylated CpGs P < 10 -100
, hypomethylated CpGs P < 10 Table S2D ).
Notably, when we analyzed the 225 significant genes upon knockdown of transcript 2 (155 upregulated and 70 downregulated) we observed that the vast majority was regulated in the opposite direction upon overexpression ( Fig. 2G ; Fischer's t-test P = 6*10 -13 and P = 0.03, respectively), whereas this was less pronounced for other transcripts.
To determine if DNAm changes upon KD of transcript 2 are reflected in corresponding gene expression changes we focused on genes with significant differentially methylated CpGs in the 5´ untranslated region (5´UTR) and up to 200 or 1,500 base pairs upstream of transcription start sites (TSS200 and TSS1500, respectively). As expected, hypermethylation of promoter regions was associated with downregulation of gene expression (Fig. 2H) . Furthermore, GO analysis revealed that differentially expressed genes upon either KD or OE of transcript 2 were enriched in complementary categories 7 for up-and downregulated genes (Figs. 2I,J). Genes downregulated by DNMT3A2 were enriched in chemokine production (e.g. interleukin 8), immunity, and leukocyte migration;
whereas upregulated genes were involved in proliferation. These results indicate that DNMT3A2-associated DNAm changes are overall reflected by corresponding gene expression changes that are relevant for hematopoietic differentiation.
DNMT3A transcripts impact on hematopoietic differentiation
Different DNMT3A variants might be relevant for proliferation and differentiation of HSPCs. CD34 + cells were stained with carboxyfluorescein succinimidyl ester (CFSE) after isolation to estimate their proliferation rate based on residual CFSE after five days post infection (n = 3). Proliferation was reduced upon downregulation of transcript 2 (Figs. 3A,B), which is in line with GO enrichment of upregulated genes upon transcript 2 overexpression. In contrast, overexpression of each of the DNMT3A transcripts resulted in a moderate increase in proliferation (Fig. 3B ).
Subsequently, we analyzed if modulation of DNMT3A variants impacts on maintenance of the surface marker CD34, as a surrogate marker for HSPCs. Downregulation of transcript 2 maintained CD34 expression even in the fraction of fast proliferating cells with more than five cell divisions (P < 0.05; n = 3; Figs. 3A,C). On the other hand, overexpression of the DNMT3A transcripts reduced the proportion of CD34 + cells in the fast proliferating fraction (Fig. 3C ). In fact, differential CD34 expression was also observed in additional independent replicates, as well as corresponding DNAm and gene expression changes, indicating that DNMT3A2 is particularly relevant for loss of CD34 expression during culture expansion of HSPCs (Supplemental Fig. S2 ).
To investigate if DNMT3A variants affect colony forming unit (CFU) potential, we seeded
HSPCs in methylcellulose at day five after infection with shRNAs or overexpression and analyzed colonies after two additional weeks of culture. Surprisingly, colonies of the erythroid lineage were significantly increased upon knockdown of transcript 4 (Fig. 3D) and reduced upon overexpression of transcript 4 (Fig. 3E) . Thus, transcript 4 seems to impact on lineage-specific hematopoietic differentiation, although it does not comprise the functional methyltransferase domain. It is conceivable that effects of this isoform are mediated by other epigenetic or transcriptional modifiers by binding to the DNA with the N-terminal region (Suetake et al. 2011) . Posttranslational modification of the Dnmt3a Nterminus was also shown to facilitate additional interactions (Chang et al. 2011 Initially, we analyzed if DNMT3A mutations in AML impact on the DNAm signature of DNMT3A2. To this end, we specifically focused on the CpGs that were differentially methylated upon knockdown of transcript 2 in HSPCs in vitro. AML samples with DNMT3A mutations revealed a significantly lower DNAm level in these DNMT3A2-associated CpGs than those without DNMT3A mutations (P = 0.03; Fig. 4A ) and these samples were therefore excluded for further analysis. Notably, DNMT3A2-exon expression in AML patients revealed a highly significant correlation with DNAm levels at CpGs that were hyper-and hypomethylated upon knockdown of transcript 2 in vitro (P < 10 -100 and P = 2*10 -37 , respectively; Fig. 4B ). In analogy, DNMT3A2-exon expression in AML was also significantly correlated to expression of the 155 upregulated and the 70 downregulated genes of the in vitro transcript 2 signature (P = 6*10 -13 and P = 0.0001, respectively; Figs. 4C,D) . Furthermore, the average expression level of these 155 genes was significantly higher in those AML patients with below median expression of the DNMT3A2-exon (P < 0.0001; Fig. 4E ). Similar results were observed when we used relative expression of the DNMT3A2-exon normalized by the overall DNMT3A expression level. Taken together, expression of DNMT3A2-exon is associated with variant-specific molecular signatures in AML.
Next, we analyzed if expression of transcript 2 might also be of clinical relevance in AML. In fact, expression of the DNMT3A2-exon was significantly lower in the AML subgroups M4 and M5 of the French-American-British (FAB) classification (Fig. 4F ).
Furthermore, it was lower in patients with poor and intermediate cytogenetic risk score as compared to patients with favorable risk score (P < 0.01 and P < 0.001, respectively).
Kaplan-Meier analysis (P = 0.019; Fig. 4G ) and Cox regression analysis (P = 0.016) indicated that AML patients with lower expression of the DNMT3A2-exon have a significantly shorter overall survival. In comparison to the established molecular parameters for AML stratification, expression of DNMT3A variants has lower prognostic value, but our results support the notion that alternative splicing of DNMT3A is also relevant for the disease.
Targeting of DNMTs to specific sites in the genome is orchestrated by a complex interplay with other proteins, transcription factors, the histone code, and long non-coding RNAs (Yang et al. 2015; Kalwa et al. 2016) . The results of this study add a new dimension to this complexity. The 27 exons of DNMT3A can be spliced into a multitude of different transcripts -although so far only five protein coding transcripts have been described. Our results demonstrate that different DNMT3A variants indeed have different transcript-specific molecular sequels that impact on hematopoietic differentiation and malignancy.
Materials & Methods
Cell culture of hematopoietic stem and progenitor cells
Umbilical cord blood (CB) was obtained after written consent according to guidelines approved by the Ethics Committee of RWTH Aachen Medical School (EK 187-08).
CD34
+ HSPCs were isolated from fresh CB using the CD34 Micro Bead Kit (Miltenyi Biotec, Bergisch-Gladbach, Germany) and cultured in StemSpan Serum-Free Expansion Medium (Stemcell Technologies, Vancouver, BC, Canada) supplemented with 10 μg/mL heparin (Ratiopharm, Ulm, Germany), 20 ng/mL thrombopoietin (PeproTech, Hamburg, Germany), 10 ng/mL stem cell factor (PeproTech), 10 ng/mL fibroblast growth factor 1 (PeproTech) and 100 U/mL penicillin/streptomycin (Lonza, Basel, Switzerland) (Walenda et al. 2011) .
Lentiviral knockdown and overexpression of DNMT3A variants
To knockdown DNMT3A transcripts we designed short hairpin RNAs (shRNAs) to target transcript-specific exons: exon 5 of transcripts 1+3 (ENSE00001486208), exon 2 of transcript 2 (ENSE00001486123), and exon 4 of transcript 4 (ENSE00001559474; Fig.   1A ). In brief, forward and reverse oligonucleotides (Metabion, Planegg, Germany;
Supplemental Table S3 ) were joined and ligated into the pLKO.1 vector (Addgene, Cambridge, MA, USA).
For constitutive overexpression, the DNMT3A transcripts were amplified from cDNA of human blood cells with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA) using various combinations of exon-specific primers (Supplemental Table S4 ) and cloned into the pLJM1-EGFP (Addgene) by replacing the EGFP gene. Successful cloning was validated by sequencing. About 200,000 HSPCs were infected one day after isolation and selected by treatment with puromycin (2.5 µg/mL; Sigma-Aldrich, St. Louis, MO, USA) at day two after infection.
Quantitative RT-PCR
Knockdown or overexpression of DNMT3A variants was analyzed by real-time quantitative PCR (RT-qPCR) using the StepOneTM Instrument (Applied Biosystems).
RNA was isolated at day 12 after infection, reverse transcribed, and amplified using the Power SYBR Green PCR Master Mix (Applied Biosystems) with transcript-specific primers (Supplemental Table S5 ). Gene expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
DNA methylation profiles
DNA methylation profiles were analyzed for KD and OE condition, each in three independent biological replicates. Genomic DNA was isolated at day 12 after lentiviral infection with the NucleoSpin Tissue kit (Macherey-Nagel, Düren, Germany). For DNAm analysis we have chosen the Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA) that covers about 480,000 representative CpG sites at single base resolution (including 99% of RefSeq genes and 96% of CpG islands) (Bibikova et al. 2011) . In comparison to genome-wide analysis with reduced bisulfite sequencing data each of these CpGs is detected in all samples with relatively precise estimates of DNAm levels. Furthermore, this microarray platform enabled straight forward comparison with datasets of TCGA. 
RNA expression profiles
Gene expression profiles were analyzed for KD and OE condition, each in three independent biological replicates. Total RNA was isolated at day 12 after infection with the NucleoSpin RNA kit (Macherey-Nagel) and analyzed with the Affymetrix Human Gene ST 1.0 platform (Affymetrix, Santa Clara, CA, USA). Raw data was normalized by RMA (Affymetrix Power Tools). Differentially expressed genes were filtered by at least 1.5-fold differential mean expression levels and adjusted P < 0.05, which were calculated in R using limma paired t-test. Gene Ontology analysis was performed with the GoMiner software (http://discover.nci.nih.gov/gominer/).
Flow cytometric analysis
Carboxyfluorescein N-succinimidyl ester (CFSE) was used to monitor the number of cell divisions (Walenda et al. 2010 
Colony Forming Unit (CFU) assay
HSPCs were infected with lentivirus and selected with puromycin as described above and expanded for five days prior to CFU assay. Subsequently, 100 cells per well were seeded in methylcellulose based medium (HSC-CFU lite with EPO; Miltenyi Biotec).
Granulocyte (CFU-G), macrophage (CFU-M), granulocyte/macrophage (CFU-GM), erythroid (BFU-E and CFU-E), and mixed colonies (CFU-GEMM) were counted according to manufacturer's instructions after 14 days (Walenda et al. 2011 ). (G) Kaplan-Meier plot indicates that lower DNMT3A2-exon expression (stratified by median) is associated with s horter overall survival. * P < 0.05, ** P < 0.01, *** P < 0.001 (Mann W hitney test).
Analysis of AML datasets
